Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $38.53 and traded as high as $38.10. Fresenius Medical Care AG & Co. shares last traded at $38.03, with a volume of 1,266 shares changing hands.

A number of brokerages have recently weighed in on FMS. Zacks Investment Research downgraded First Merchants from a “hold” rating to a “sell” rating in a report on Monday, July 1st. Barclays reiterated a “hold” rating and issued a $14.00 target price on shares of MACOM Technology Solutions in a report on Thursday, June 20th. DZ Bank reiterated a “neutral” rating on shares of Gerresheimer in a report on Thursday, July 11th. Royal Bank of Canada dropped their target price on from GBX 3,000 ($39.20) to GBX 2,900 ($37.89) and set an “outperform” rating on the stock in a report on Thursday, June 6th. Finally, Commerzbank reiterated a “hold” rating and issued a $54.00 target price on shares of Fresenius Medical Care AG & Co. in a report on Thursday, May 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Fresenius Medical Care AG & Co. presently has an average rating of “Hold” and a consensus target price of $53.05.

The business has a fifty day moving average of $38.55. The stock has a market cap of $24.24 billion, a PE ratio of 16.91, a price-to-earnings-growth ratio of 2.80 and a beta of 1.43. The company has a current ratio of 1.02, a quick ratio of 0.79 and a debt-to-equity ratio of 0.73.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.07. Fresenius Medical Care AG & Co. had a return on equity of 10.27% and a net margin of 11.94%. The firm had revenue of $4.13 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the prior year, the company posted $0.91 earnings per share. The firm’s revenue was up 3.9% on a year-over-year basis. On average, analysts forecast that Fresenius Medical Care AG & Co. will post 2.4 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. Magellan Asset Management Ltd increased its holdings in Fresenius Medical Care AG & Co. by 52.3% in the fourth quarter. Magellan Asset Management Ltd now owns 1,433 shares of the company’s stock worth $46,000 after buying an additional 492 shares during the last quarter. Hartwell J M Limited Partnership boosted its position in Fresenius Medical Care AG & Co. by 4.4% during the first quarter. Hartwell J M Limited Partnership now owns 16,500 shares of the company’s stock worth $669,000 after purchasing an additional 700 shares during the period. Harvest Group Wealth Management LLC bought a new stake in Fresenius Medical Care AG & Co. during the first quarter worth approximately $29,000. NEXT Financial Group Inc bought a new stake in Fresenius Medical Care AG & Co. during the second quarter worth approximately $29,000. Finally, Rehmann Capital Advisory Group boosted its position in Fresenius Medical Care AG & Co. by 46.7% during the first quarter. Rehmann Capital Advisory Group now owns 2,565 shares of the company’s stock worth $104,000 after purchasing an additional 817 shares during the period. Hedge funds and other institutional investors own 1.46% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile (NYSE:FMS)

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: What is a closed-end mutual fund (CEF)?

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.